Pulmatrix Announces 2025 Financial Results, Plans Cullgen Merger

Thursday, Feb 26, 2026 8:09 am ET1min read
PULM--

• Pulmatrix reports year-end and Q4 2025 financial results. • Company plans to license or monetize migraine and inhalation assets. • Interim CEO Peter Ludlum comments on the proposed merger with Cullgen. • Pulmatrix focuses on advancing steps to complete the merger. • Company is a biopharmaceutical company with a patented iSPERSE technology. • Pulmatrix develops novel inhaled therapeutic products for migraine and respiratory diseases.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet